Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1351 to 1365 of 1877 results for do not dos

  1. What are the long-term outcomes of different management strategies for primary hyperparathyroidism? Which strategies are most cost effective?

    parathyroid surgery. Evidence suggests that around one‑third of people who do not have symptoms or indications for surgery will go on to...

    Research recommendation
    Published
    25 October 2019

  2. Biomarker tests to help diagnose preterm labour in women with intact membranes (HTG476)

    Evidence-based recommendations on biomarker tests to help diagnose preterm labour in women with intact membranes. The tests are Actim Partus, PartoSure and the Rapid fetal fibronectin (fFN) 10Q Cassette Kit (at thresholds other than 50 nanograms/millilitre).

    HealthTech guidance
    Published
    4 July 2018
    View recommendations

    Sections for HTG476

  3. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (TA243)

    Evidence-based recommendations on rituximab for the first-line treatment of stage III–IV follicular lymphoma.

    Technology appraisal guidance
    Published
    25 January 2012
    View recommendations

    Sections for TA243

  4. Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)

    Evidence-based recommendations on panobinostat (Farydak) for treating multiple myeloma after at least 2 previous treatments.

    Technology appraisal guidance
    Published
    27 January 2016
    View recommendations

    Sections for TA380

  5. Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)

    Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.

    Technology appraisal guidance
    Published
    4 June 2015
    View recommendations

    Sections for TA341

  6. Alitretinoin for the treatment of severe chronic hand eczema (TA177)

    Evidence-based recommendations on alitretinoin (Toctino) for treating severe chronic hand eczema in adults.

    Technology appraisal guidance
    Published
    26 August 2009
    View recommendations

    Sections for TA177

  7. Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)

    Evidence-based recommendations on trametinib (Mekinist) with dabrafenib (Tafinlar) for adults with unresectable or metastatic melanoma that has a BRAF V600 mutation.

    Technology appraisal guidance
    Published
    22 June 2016
    View recommendations

    Sections for TA396

  8. Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (HST31)

    Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity and hyperphagia in Bardet-Biedl syndrome in people 6 years and over, only if they are between 6 and 17 years when treatment starts.

    Highly specialised technologies guidance
    Published
    22 May 2024
    View recommendations

    Sections for HST31

  9. Digital technologies to support self-management of COPD: early value assessment (HTG736)

    Early value assessment (EVA) guidance on digital technologies to support self-management of COPD.

    HealthTech guidance
    Last updated
    3 February 2026
    View recommendations

    Sections for HTG736

  10. What is the most clinically and cost-effective pathway for diagnosing clinically significant prostate cancer?

    Likert score is 1 or 2 because there was some evidence that this is safe to do. However, there is a small risk that in some cases...

    Research recommendation
    Published
    7 January 2022

  11. Care of dying adults in the last days of life (QS144)

    This quality standard covers the clinical care of adults (aged 18 and over) who are dying, during the last 2 to 3 days of life. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    2 March 2017
    View quality statements

    Sections for QS144

  12. What is the most clinically and cost-effective pathway for diagnosing clinically significant prostate cancer?

    Likert score is 1 or 2 because there was some evidence that this is safe to do. However, there is a small risk that in some cases...

    Research recommendation
    Published
    25 October 2019

  13. What is the natural history of people with a Likert score on MRI of less than 3 without biopsy at long-term follow‑up?

    Likert score is 1 or 2 because there was some evidence that this is safe to do. However, there is a small risk that in some cases...

    Research recommendation
    Published
    25 October 2019

  14. Extracorporeal shockwave therapy for Achilles tendinopathy (HTG426)

    Evidence-based recommendations on extracorporeal shockwave therapy for treating Achilles tendinopathy in adults. This involves passing shockwaves through the skin to the affected area.

    HealthTech guidance
    Published
    21 December 2016
    View recommendations

    Sections for HTG426

  15. ORA G3 to measure corneal hysteresis (MIB150)

    NICE has developed a medtech innovation briefing (MIB) on ORA G3 to measure corneal hysteresis .

    Medtech innovation briefing
    Published
    18 June 2018